Angiogenesis is a critical event for solid tumor growth and metastasis. Within a given microenvironment, the angiogenic response is determined in part by the balance between angiogenesis inducers and inhibitors. The aim of this study was to establish a thrombospondin -1 ( TSP -1 ) ( an antiangiogenic gene ) expression vector, and to determine the feasibility for use of TSP -1 in prostate cancer gene therapy. The results of this study showed that pCR -TSP -1, the cloned TSP -1 expression plasmid vector, expressed the TSP -1 gene efficiently in DU145, a human prostate cancer cell line. pCR -TSP -1 did not exert any significant growth inhibitory activity on the tested cell line in vitro. However, TSP -1 overexpression inhibited the growth of DU -145 xenografts in Balb / c nude mice when directly transfected with pCR -TSP -1 in combination with a liposomal agent ( DOSPER ) . Histological analysis showed that there were extensive areas of necrosis in the TSP -1 overexpressing tumors, whereas no necrotic foci were observed in the control tumors. Furthermore, the microvessel density was lower in the TSP -1 overexpressing tumors compared to the control tumors. These results suggest that TSP -1 may be a potentially useful gene for prostate cancer gene therapy. Cancer Gene Therapy ( 2000 ) 7, 1537 ± 1542
P
rostate cancer is both the most frequently diagnosed form of cancer and the second leading cause of cancer death in men after lung cancer in the Western world. 1 Recently, a great deal of scientific interest has focused on the extratumoral processes associated with tumor progression in prostate cancer, one of which is angiogenesis. 2 Angiogenesis is the mechanism utilized by the human body to produce new blood vessels. It occurs as a normal physiological process during prenatal development, the female reproductive cycle, and wound healing. 3, 4 However, abnormal angiogenesis also occurs during the development of solid tumors and their metastases. Tumors require blood vessels to supply nutrients and oxygen and with access to sufficient blood supply, the cancer is free to grow and spread. Without an adequate blood supply, the tumor cannot grow larger than a pea and is thus nonlethal. 5 ± 8 To allow for continuous growth, cancer cells release substances that induce angiogenesis resulting in the formation of new capillaries. Within a given microenvironment, the angiogenic response is determined in part by a balance between angiogenesis inducers (VEGF, bFGF, IL -8, etc. ) and inhibitors (angiostatin, endostatin, thrombospondin, etc. ). 8 ± 12 Thrombospondin-1 (TSP -1) is a multifunctional, Mr 450,000 trimeric glycoprotein that can prevent the induction of neovascularity in the rat cornea. 13 When overexpressed in cancer cells, it can block angiogenesis, tumor growth, and metastasis in various types of cancer cells. 14 ± 17 Furthermore, it has been shown that TSP -1 can modulate endothelial cell adhesion, motility, and growth in addition to exerting an antiangiogenic effect on cord formation. 18 Moreover, human TSP -1 has been found to inhibit neovascularization by inducing the receptor-mediated microvascular endothelial cells. 19 Despite a number of studies 20 ± 26 considerable controversies still remain as far as the prognostic value of angiogenesis in prostate cancer is concerned. However, there is strong evidence that angiogenesis in prostate cancer correlates significantly with the progress of prostate cancer, including the tumor stage, grade, metastasis, and clinical outcome. 20,22,23,27 ± 30 However, with respect to the role of TSP -1 in prostate cancer progression, much less is known. Recently, it was observed that TSP -1 expression in prostate cancer was reduced significantly when compared to benign prostatic hyperplasia. Furthermore, TSP -1 expression in metastatic prostate cancer was even lower than that in localized prostatic cancer (unpublished data ).
In this investigation, a TSP -1 expression vector for gene therapy in prostate cancer was developed and it was determined whether the TSP -1 gene, expressed by the cloned vector, could affect human prostate cancer cell growth in the nude mouse xenograft model.
MATERIALS AND METHODS
Cell lines and cell maintenance DU145, a human prostate cancer cell line ( ATCC ), was maintained in RPMI1640 supplemented with 10% fetal bovine serum ( Gibco -BRL, Grand Island, NY ), and 1 unit / mL gentamycin.
Cloning of the TSP -1 expression vector
Two oligonucleotide primers for the reverse transcription ± polymerase chain reaction (RT-PCR ) amplification of the TSP -1 cDNA using total RNA isolated from normal human blood cell as the templates were designed. The oligonucleotide primer sequences used are as follows: 5
H -ATG GGG CTG GCC TGG -3 H , sense, and 5 H -TTA GGG ATC TCT ACA TTC GTA TTT CA -3 H , antisense, for TSP -1 cDNA. The TSP -1 expression vector was constructed using standard procedures. The base plasmid, pCR 1 3.1-TOPO ( Invitrogen, Carlsbad CA ), contains a cytomegalovirus ( CMV ) promoter. The TSP -1 cDNA fragments (3.5 kb) obtained by RT-PCR were cloned into the multiple cloning site of pCR 1 3.1-TOPO, named pCR -TSP -1, and sequenced using an automated DNA sequencer (ABI Prism, Perkin -Elmer Cetus Foster, CA ).
DNA transfection by liposome
The cells were seeded ( 5Â10 5 cells/well ) in 2 mL of the complete growth medium in a six -well culture plate, and cultured (378C, 5% CO 2 ) until the cells were 70 ± 80% confluent. Ten microliters of the liposomal agent (DOSPER ) ( Gibco -BRL, Mannheim, Germany ) and 10 g of plasmid DNA were diluted in Dulbecco's phosphate -buffered saline ( DPBS ) to a total volume of 100 L and then gently mixed in polystyrene tubes. The resulting solution was then allowed to form complexes at room temperature for 15 minutes. When the complexes were formed, the cells were rinsed once with 2 mL of serum -free medium. For the transfection, 0.9 mL of serum -free medium was added to the tube containing the liposome ±DNA complexes. The diluted complex solution was mixed gently, overlaid onto the rinsed cells then incubated for 4 hours. Following incubation, the medium was replaced with fresh culture medium.
Western blot analysis
The cells were collected at 24, 48, and 72 hours after transfection. The floating cells collected and pelleted by centrifugation. The pellets were resuspended in a minimal amount of lysis buffer (1 M Tris ±HCl, 0.5 M NaCl, 0.5 M EDTA, 0.7 mg /mL pepstatin, and 1 mM PMSF ), and homogenized by passing through a 26 -gauge needle. The concentration of protein was determined by BCA assay ( Bio -Rad, Hercules, CA ). Proteins were separated on a 4 ± 12% tris -glycine gradient gel ( NOVEX 2 ). After separation, proteins were transferred to Hybond 2 -P membranes ( Amersham Pharmacia Biotech, Piscataway, NJ ). The membranes were blocked with 5% skim milk in a TBS -T ( Tris -buffered saline, 1% Tween -20 ) buffer. Human TSP -1 antibodies ( Neo MARKERS, Fremont, CA ) were used for analysis. The signals were developed by an ECL detection system (Intron, Seoul, Korea) .
Cell growth inhibition assay
The cells were seeded (1Â10 4 cells/well) in 200 L of the growth medium in a 96 -well plate, and an MTT assay 31 was performed at 0, 24, 48, and 72 hours following the start of transfection.
Growth of xenografts in nude mice
The subcutaneous (s.c. ) tumors were generated by injecting 1Â10 6 DU145 cells in 50 L DPBS into the flank of eight 5-week -old male BALB /c (nu /nu ) mice (four mice as treatment group; four mice as control group ) . The primary tumor had grown to about 0.5 cm diameter, 3 weeks after s.c. injection. Afterwards, a pCR -TSP -1 vector (10 g) or pCR 1 3.1 vector ( 10 g, control ) mixture with DOSPER (10 L ) (diluted in DPBS to 50 L ) was injected directly into the tumor xenograft at 0, 3, and 10 days. The smallest and largest tumor diameter were measured weekly, using a digital caliper, and the tumor volumes were calculated using the following formula:
The mice were sacrificed 4 weeks after the initial intratumor injection of the DNA and DOSPER mixtures for histological examination.
Immunohistochemical staining
Four-micrometer-thick sections were cut from paraffin blocks containing the tumors and were stained in the following manner: The sections were deparaffinized by incubating at room temperature for 10 minutes in xylene three times. The sections were rehydrated and treated with 3% H 2 O 2 in methanol for 30 minutes to block any endogenous peroxidase activity. The slides were then subjected to an antigen retrieval procedure by microwaving the sections in a 10 mM citrate buffer for 10 minutes. Subsequently, the sections were cooled to room temperature over 20 minutes, and washed extensively with distilled water. The sections were incubated in 5% bovine serum albumin (Vector Laboratories, Burlingame, CA ) in a phosphate -buffered saline solution for 30 minutes to block the nonspecific binding of antibodies. The sections were then incubated with monoclonal antibodies against mouse CD31 (PharMingen, San Jose, CA ) for 60 minutes at room temperature, and used at 1:1000 dilutions. Immunohistochemical staining was accomplished through the use of a labeled streptavidin ± biotin ( LSAB ) kit from Dako ( Carpinteria, CA ) and operated according to the manufacturer's instructions. Diaminobenzidine was used as a chromogen to detect the immunostaining as a brown product and the sections were counterstained with 1% Mayer's hematoxylin ( Sigma, St. Louis, MO ). The stained sections were examined and photographed using an Olympus microscope and camera.
Computer -assisted morphometric analysis of tumor vessels
The intratumoral MVD (microvascular density ) was analyzed using an Olympus IX 50 -11 microscope ( Olympus Optical, Tokyo, Japan ). The images were captured with a Spot digital camera ( JVC KT1308U, JVC, Tokyo, Japan ) , and morphometric analyses were performed using the Image-Pro PLUS V3.0 for Windows software program ( Media Cybernetics, Silver Spring, MD ). The field of high microvessel density (``hot spots'') within the tumor area was examined under light microscopy with 100-fold magnification on each section, and the vascular endothelia cell density was determined.
Statistical analysis
Statistical analysis was performed using the SPSS 8.0 for windows ( SPSS, Chicago, IL ) package. The statistical significance was defined as P < .05 and the results are presented as the mean SE. The significance of the difference was analyzed by Mann -Whitney rank sum test.
RESULTS

Sequence of TSP -1
The DNA fragments of TSP -1 ( 3.5 kb ) were obtained by RT-PCR amplification of the RNA from normal human blood cells, and cloned into the pCR 1 3.1 vector. They were then sequenced using an automated sequencer. The sequence was compared with those published in GENE BANK (Gene Bank sequence HSTHROMR, Acc# X04665 ), where no difference was found (date not shown) .
TSP -1 express efficiently in DU145 cells
To determine the activity of the cloned TSP -1 expression vector, the pCR -TSP -1 was transfected into the DU145 cells. The RT-PCR and Western blot assays were performed at 24, 48, and 72 hours following transfection. The results showed that TSP -1 was expressed efficiently in the target cells. In addition, the TSP -1 mRNA and protein expression level in the DU145 cells was highest after 24 hours (Figs 1  and 2 ).
TSP -1 expressed by cloned vector has no effect on the growth of DU145 cells in vitro
To determine whether the TSP -1 gene expressed by a cloned vector can affect the growth of the DU145 cell line in vitro, the pCR -TSP -1 and pCR 1 3.1 (control ) vector were transfected into the DU145 cells. The MTT assay was performed at 0, 24, 48, and 72 hours following transfection. Compared to the control, the results showed that the TSP -1 expression vector had almost no effect on the growth of the DU145 cells in vitro (Fig 3 ) .
TSP -1 overexpression suppresses the growth of prostate cancer xenograft in vivo
A mixture of the pCR -TSP -1 vector or pCR 1 3.1 vector with DOSPER was injected directly into tumor xenograft at 0, 3, and 10 days, when the primary tumor had grown to approximately 0.5 cm in diameter. This usually occurred 3 weeks after the s.c. injection of the DU -145 cell line into 
Histological characteristics of TSP -1 overexpression tumor
The volumes of the TSP -1 overexpressing tumors were markedly smaller than the controls (P < .05 ). However, histological analysis ( hematoxylin /eosin staining ) indicated extensive areas of necrosis in all the TSP -1 overexpressing tumors ( Fig 6B ) , whereas almost no necrotic foci were located in the control tumors ( Fig  6A ) . Immunohistochemical analysis demonstrated that the significantly ( P <.05, Mann -Whitney test ) strong CD -31 ( mouse ) staining in the pCR 1 3.1 vector ± treated tumor ( 18.473 1.133% ) , was predominantly localized to the tumoral endothelial cells (Fig 7A ) and decreased CD -31 staining in the pCR -TSP -1 vector ± treated tumor ( 7.341 1.023% ) (Fig 7B ) was identified. Moreover, the average area per vessel was remarkably smaller in the pCR -TSP -1 vector ±treated tumor, compared to the controls. 
DISCUSSION
Cancer growth requires the proliferation of both malignant and normal cells. There are several anticancer treatment modalities currently available, including surgery, chemotherapy, radiation therapy, and immunotherapy, that have been envisioned to target primarily the malignant cell. Research over the past 30 years has reinforced the hypothesis put forth by Folkman 32 that, without the proliferation of normal cells, especially endothelial cells, a tumor cannot grow beyond the size of a colony. This finding means that both normal and malignant cells are involved in tumor growth, as are the chemical and mechanical signaling pathways that interconnect them. All these are valid targets for therapeutic intervention. The integration of therapeutics directed toward the vascular components, extracellular, matrix components, and stromal and infiltrating cells, with classical cytotoxic anticancer therapies, may be regarded as a systems approach to cancer treatment. 33 There is evidence that tumor angiogenesis is mediated by an imbalance in favor of angiogenesis-stimulating ( angiogenic ) over angiogenesis -inhibiting (antiangiogenic ) factors. Some of the most frequently examined angiogenic factors are the vascular endothelial growth factor ( VEGF ), acidic/ basic fibroblast growth factors ( a/ b -FGF ), and the platelet -derived endothelial cell growth factor ( PDECGF ). 34 ± 41 These angiogenic factors might be released either by the tumor cell and/ or host immune cells ( i.e., macrophages ) . Important angiogenesis inhibitors are angiostatin, endostatin, and thrombospondin. 9, 10, 12 To date, these are a paucity of studies focusing on the expresses of the angiogenesis -associated factors in prostate cancer. Furthermore, it is unclear what role TSP -1 has on prostate cancer progress.
The experiments reported in this investigation have established a TSP -1 expression plasmid vector. In addition, it was determined that the established vector expresses TSP -1 efficiently in DU145, a prostate cancer cell line. Compared to the controls, although there was almost no effect on proliferation of DU145 cells in vitro, TSP -1, expressed by the cloned vector, inhibited the growth of prostate cancer xenograft dramatically. Furthermore, the tumor MVD treated by the TSP -1 expression vector was much lower than the controls, and the volume of the TSP -1 treated tumors were much smaller than the controls. Histological analysis indicated extensive areas of necrosis in all the TSP -1-transfected tumors, whereas almost no necrotic foci were found in the control tumors. These results suggest that in the nude mouse model, TSP -1 efficiently inhibits the growth of prostate cancer xenografts. In addition, the antitumoral effect of TSP -1 was not due to direct inhibition of tumor cell proliferation, but was associated with significant inhibition of tumor angiogenesis.
A cure of cancer means that all malignant cells should be eradicated. Until now, many kinds of anticancer strategies have been attempted including gene therapy. Especially in the area of gene therapy, most research has focused on cytokine, tumor suppressor, and suicide genes as the therapeutic genes. To cure cancer, these therapeutic genes should be delivered to almost all target cells, although there is a``bystander effect'' that might exist for some genes. However, it is difficult or almost impossible to deliver the therapeutic gene to all target cells. The antiangiogenic strategy like the one reported in this study is different than other strategies, as it does not directly target the tumor cells. The antiangiogenic gene can induce the necrosis of tumor cells, even if the gene is delivered to only some of the target cells, just enough to adjust the balance of angiogenic stimulators and inhibitors in the nearby miroenvironment, which blocks the blood supply of the tumoral tissues by antiangiogenesis. In this study, necrosis foci were located only in the central area of the treated tumors, but complete shrinkage of tumors did not occur. It might be thought that the high level of TSP -1 expression and the lack of vasculature were limited in the central area of the tumor because only the centrally located tumor cells were transfected with the TSP -1 expression vector when the intratumor DNA and DOSPER mixture was injected. Therefore, although complete inhibition of tumor growth was not accomplished in this study, it is believed that it still might be possible to thoroughly control tumor growth by develo ping a better delivery system and way of administration.
Therefore, our results suggest that cloned plasmid vector expressed the TSP -1 gene efficiently in DU145 cells and greatly reduced prostate cancer tumor growth and angiogenesis in the mouse xenograft model. Thus, TSP -1 may be a potentially useful gene for prostate cancer gene therapy.
